source · text/markdown
source_437d21f907c54837
sha256 88353b055f8d53a32c667671d3f6fd300db99acd3c6ecfc80adfb220ffd47b26
by researka:v2 · 2026-06-14 01:32:03.074737+04:00
**Selected angle:** `boundary_condition` ## One-sentence thesis Across 5 independently cited sources, the evidence converges on one bounded claim: rapamycin extends lifespan / reduces mortality in mice across diverse stocks, ages, and dosing regimens. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate. **Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication. ## Why this is surprising Real tension: the interesting signal is where the evidence stops generalizing — the memo is not a broad topic summary but a testable boundary condition. ## Evidence Landscape **Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned? ## Evidence receipts - `fact_id=318859` (`A_core`) — Rapamycin extends the median mice life span by 10% doi=10.7759/cureus.98514 - `fact_id=rapamycin/transient/bitto_2016/lifespan_extension` (`A_core`) — 3 months of rapamycin extended remaining lifespan by ~60% in middle-aged mice doi=10.7554/eLife.16351 - `fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496 - `fact_id=rapamycin/itp/miller_2014/dose_response_high_male` (`A_core`) — rapamycin at 42 ppm extended male median lifespan by 23% doi=10.1111/acel.12194 - `fact_id=rapamycin/itp/harrison_2009/lifespan_female` (`A_core`) — rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm) doi=10.1038/nature08221 ## Context receipts _Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._ - `fact_id=rapamycin/itp/miller_2014/dose_response_high_female` (`A_core`) — rapamycin at 42 ppm extended female median lifespan by 26% doi=10.1111/acel.12194 - `fact_id=rapamycin/transient/bitto_2016/lifespan_male` (`A_core`) — 3 months of rapamycin extended median lifespan by 52% in male middle-aged mice doi=10.7554/eLife.16351 ## What this changes Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis. ## Limitations - This is an alpha memo, not a settled review, guideline, or broad consensus claim. - This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review. - Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below. - The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof. - Independent receipts fail to reproduce the claimed contrast. - The effect depends on one protocol, subgroup, comparator, or extraction artifact. ## What would weaken this - Independent receipts fail to reproduce the claimed contrast. - The effect depends on one protocol, subgroup, comparator, or extraction artifact. ## Strongest counter-evidence - _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "27f60a7b-7f92-424c-bb44-65d749454a16",
"title": "Rapamycin extends lifespan / reduces mortality in mice across diverse stocks, ages, and dosing regimens"
}